middle.news
Clarity’s Cu-SAR-bisPSMA doubles lesion detection in Phase II trial
1:04pm on Thursday 30th of April, 2026 AEST
•
Healthcare
Read Story
Clarity’s Cu-SAR-bisPSMA doubles lesion detection in Phase II trial
1:04pm on Thursday 30th of April, 2026 AEST
Key Points
Co-PSMA trial shows 2.6x lesion detection improvement
AMPLIFY Phase III trial recruitment completed with 232 patients
Manufacturing agreements with Nucleus RadioPharma and Theragenics secured
SECuRE theranostic trial reports promising efficacy and safety
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Clarity Pharmaceuticals (ASX:CU6)
OPEN ARTICLE